Erasca Stock

erasca.comHealthcare / BioTech & PharmaFounded: 2018Funding to Date: $64MM

Erasca is a biotechnology company committed to solving oncology’s hardest problems.

Register for Details

For more details on financing and valuation for Erasca, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Erasca.

Register Today

Team

Management Team

Gary Yeung
Chief Business Officer
Jonathan Lim MD
Founder and Executive Chairman

Board Members

James Bristol Ph.D
Jonathan Lim MD
Pratik Multani MD
Alexander Casdin

Other companies like Erasca in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Erasca Brings In $36M More For Series B For Cancer Treatments
Erasca will use the funding to drive corporate development efforts and further advance the company’s in-house drug discovery pipeline.
San Diego’s Erasca Lands $200M In Series B Round 
San Diego-based cancer treatment startup Erasca raised $200 million in a new round of funding, the company announced Monday.
Erasca Raises $200M in Series B Financing | FinSMEs
Erasca, a San Diego, CA-based develper of oncology programs, completed a $200m Series B financing round co-led by Arch Venture Partners and Cormorant Asset Management
Updated on: Oct 1, 2023